Timothy P. Martens

Timothy P. Martens

Auto-generated profile, based on publicly available information

Timothy P. Martens

Department of Biomedical Engineering, Columbia University, New York, New York

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in Tissue Engineering Part B: Reviews
Verified
Journal Article
Closed access
Gordana Vunjak-NovakovicGordana Vunjak-Novakovic
Gordana Vunjak-Novakovic
NTNina Tandon
Nina Tandon
AGAmandine Godier
Amandine Godier
RMRobert Maidhof
Robert Maidhof
AMAnna Marsano
Anna Marsano
MRMilica Radisic
Milica Radisic
Cardiac tissue engineering aims to create functional tissue constructs that can reestablish the structure and function of injured myocardium. Engineered constructs can also serve as high-fidelity models for studies of cardiac development and disease. In a general case, the biological potential of the cell—the actual “tissue engineer”—is mobilized by providing highly controllable three-dimensional environments that can mediate cell differentiation and functional assembly. For cardiac regeneration, some of the key requirements that need to be met are the selection of a human cell source, establishment of cardiac tissue matrix, electromechanical cell coupling, robust and stable contractile function, and functional vascularization. We review here the potential and challenges of cardiac tissue engineering for developing therapies that could prevent or reverse heart failure.

1 February 2007 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
MRMark J. Russo
Mark J. Russo
JCJonathan M. Chen
Jonathan M. Chen
RSRobert A. Sorabella
Robert A. Sorabella
TMTimothy P. Martens
Timothy P. Martens
MGMauricio Garrido
Mauricio Garrido
YNYoshifumi Naka
Yoshifumi Naka

20 April 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
AGAmandine F. G. Godier-Furnémont
Amandine F. G. Godier-Furnémont
TMTimothy P. Martens
Timothy P. Martens
MKMichael S. Koeckert
Michael S. Koeckert
LWLeo Wan
Leo Wan
JPJonathan Parks
Jonathan Parks
Gordana Vunjak-NovakovicGordana Vunjak-Novakovic
Gordana Vunjak-Novakovic
Control over cell engraftment, survival, and function remains critical for heart repair. We have established a tissue engineering platform for the delivery of human mesenchymal progenitor cells (MPCs) by a fully biological composite scaffold. Specifically, we developed a method for complete decellularization of human myocardium that leaves intact most elements of the extracellular matrix, as well as the underlying mechanical properties. A cell–matrix composite was constructed by applying fibrin hydrogel with suspended cells onto decellularized sheets of human myocardium. We then implanted this composite onto the infarct bed in a nude rat model of cardiac infarction. We next characterized the myogenic and vasculogenic potential of immunoselected human MPCs and demonstrated that in vitro conditioning with a low concentration of TGF-β promoted an arteriogenic profile of gene expression. When implanted by composite scaffold, preconditioned MPCs greatly enhanced vascular network formation in the infarct bed by mechanisms involving the secretion of paracrine factors, such as SDF-1, and the migration of MPCs into ischemic myocardium, but not normal myocardium. Echocardiography demonstrated the recovery of baseline levels of left ventricular systolic dimensions and contractility when MPCs were delivered via composite scaffold. This adaptable platform could be readily extended to the delivery of other reparative cells of interest and used in quantitative studies of heart repair.

27 November 2007 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
MRMilica Radisic
Milica Radisic
HPHyoungshin Park
Hyoungshin Park
TMTimothy P. Martens
Timothy P. Martens
JSJohanna E. Salazar‐Lazaro
Johanna E. Salazar‐Lazaro
WGWenliang Geng
Wenliang Geng
Gordana Vunjak-NovakovicGordana Vunjak-Novakovic
Gordana Vunjak-Novakovic

1 August 2009 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Closed access
WGWarren L. Grayson
Warren L. Grayson
TMTimothy P. Martens
Timothy P. Martens
GEGeorge M. Eng
George M. Eng
MRMilica Radisic
Milica Radisic
Gordana Vunjak-NovakovicGordana Vunjak-Novakovic
Gordana Vunjak-Novakovic

1 March 2009 in Cell Transplantation
Verified
Journal Article
Open access
TMTimothy P. Martens
Timothy P. Martens
AGAmandine F. G. Godier
Amandine F. G. Godier
JPJonathan J. Parks
Jonathan J. Parks
Leo Q. WanLeo Q. Wan
Leo Q. Wan
MKMichael S. Koeckert
Michael S. Koeckert
Gordana Vunjak-NovakovicGordana Vunjak-Novakovic
Gordana Vunjak-Novakovic
Heart disease is the leading cause of death in the US. Following an acute myocardial infarction, a fibrous, noncontractile scar develops, and results in congestive heart failure in more than 500,000 patients in the US each year. Muscle regeneration and the induction of new vascular growth to treat ischemic disorders of the heart can have significant therapeutic implications. Early studies in patients with chronic ischemic systolic left ventricular dysfunction (SLVD) using skeletal myoblasts or bone marrow-derived cells report improvement in left ventricular ejection function (LVEF) and clinical status, without notable safety issues. Nonetheless, the efficacy of cell transfer for cardiovascular disease is not established, in part due to a lack of control over cell retention, survival, and function following delivery. We studied the use of biocompatible hydrogels polymerizable in situ as a cell delivery vehicle, to improve cell retention, survival, and function following delivery into the ischemic myocardium. The study was conducted using human bone marrow-derived mesenchymal stem cells and fibrin glue, but the methods are applicable to any human stem cells (adult or embryonic) and a wide range of hydrogels. We first evaluated the utility of several commercially available percutaneous catheters for delivery of viscous cell/hydrogel suspensions. Next we characterized the polymerization kinetics of fibrin glue solutions to define the ranges of concentrations compatible with catheter delivery. We then demonstrate the in vivo effectiveness of this preparation and its ability to increase cell retention and survival in a nude rat model of myocardial infarction.